Fairvalue-Calculator Fairvalue-Calculator
EN DE

X4 Pharmaceuticals, Inc (XFOR) Fair Value & Analysis

Healthcare · US · Market cap $386M

Price$3.99
Fair Value$1.67
Upside-58.1%
Quality95/100
Evidence: Low Range $1.10 – $2.09

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

X4 Pharmaceuticals, Inc (XFOR) currently trades at $3.99, while our model-based Fair Value estimate is $1.67 — implying the stock looks roughly 58.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is X4 Pharmaceuticals, Inc (XFOR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.67 versus a price of $3.99 — about −58% (overvalued). Model-based estimate, not financial advice.
What is the fair value of XFOR?
Our 21-model fair value for X4 Pharmaceuticals, Inc is $1.67 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.99.
What is the quality score of XFOR?
X4 Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.